GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
Rhea-AI Summary
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators, announced CEO Marc Hertz's participation in a Virtual Investor "What This Means" segment. During the presentation, Dr. Hertz discussed the company's recently announced 6-week interim biomarker data from their ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis (IPF).
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, GRI declined 37.56%, reflecting a significant negative market reaction. Argus tracked a peak move of +13.3% during that session. Argus tracked a trough of -42.0% from its starting point during tracking. Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $5M at that time. Trading volume was exceptionally heavy at 10.2x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Access the “What This Means” segment here
LA JOLLA, CA, July 31, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a Virtual Investor “What This Means” segment.
For the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI, discussed the Company’s recently announced 6-week interim biomarker data from its ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis (“IPF”).
The “What This Means” segment can be accessed here.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
FAQ
What did GRI Bio CEO discuss in the Virtual Investor segment?
What is GRI Bio's main focus in drug development?
What clinical trial is GRI Bio currently conducting?
Who is the CEO of GRI Bio (NASDAQ: GRI)?
